Parallax Volatility Advisers
MRSN

Parallax Volatility Advisers’s Mersana Therapeutics MRSN Stock Holding History

Parallax Volatility Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-360
Closed -$85K – 2165
2021
Q3 		$85K Buy
+360
New +$105K ﹤0.01% 1783

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Parallax Volatility Advisers's MRSN Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 1,148 shares — an estimated $534K sold.

Parallax Volatility Advisers first reported a position in MRSN in Q4 2017 and held it in 2 quarters. The position peaked at $534K in Q3 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,148 Mersana Therapeutics shares in Q4 2020, an estimated $534K.
  • Parallax Volatility Advisers first reported a position in Mersana Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Mersana Therapeutics position peaked at $534K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.